4.5-Diphenyl-2-oxazolcarboxylsaeure-aethylester | 93729-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4.5-Diphenyl-2-oxazolcarboxylsaeure-aethylester
• 英文别名: 4,5-diphenyl-oxazole-2-carboxylic acid ethyl ester；ethyl 4,5-diphenyl-2-oxazolecarboxylate；ethyl 4,5-diphenyl-1,3-oxazole-2-carboxylate
• CAS: 93729-28-3
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: WKSYCGROFUCSHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 4.5-Diphenyl-2-oxazolcarboxylsaeure-aethylester 反应 3.5h， 以74%的产率得到1-(4,5-diphenyloxazole-2-carbonyl)-4-methylpiperazine
  参考文献：
  名称：

  EP1621537

  摘要：

  公开号：
• 作为产物：
  描述：

  oxalic acid ethyl ester-(α'-oxo-bibenzyl-α-yl ester) 在 ammonium acetate 、 溶剂黄146 作用下， 反应 14.0h， 生成 4.5-Diphenyl-2-oxazolcarboxylsaeure-aethylester
  参考文献：
  名称：

  EP1621537

  摘要：

  公开号：

文献信息

• Five-membered heterocyclic derivative
  申请人：Okayama Toru

  公开号：US20060189591A1

  公开（公告）日：2006-08-24

  The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

  本发明涉及一种由公式（I）表示的化合物：该化合物的盐，或该化合物或盐的溶剂化物；含有任何该化合物、盐和溶剂化物的药物；含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂；以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。
• NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS
  申请人：Makriyannis Alexandros

  公开号：US20100063050A1

  公开（公告）日：2010-03-11

  Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for the CB1 or CB2 cannabinoid receptor. Also disclosed are pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect.

  本发明涉及一种具有生物活性的异杂环吡咯类似物，如咪唑、噻唑、噁唑和吡唑，能够与CB1和/或CB2大麻素受体相互作用。其中一方面揭示了异杂环吡咯类似物作为CB1和/或CB2受体的拮抗剂。另一方面揭示了异杂环吡咯类似物具有选择性作用于CB1或CB2大麻素受体。还揭示了利用所述类似物的制药制剂和治疗有效量的方法，以提供生理效应。
• Heteropyrrole analogs acting on cannabinoid receptors
  申请人：University of Connecticut

  公开号：US08084451B2

  公开（公告）日：2011-12-27

  Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for the CB1 or CB2 cannabinoid receptor. Also disclosed are pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect.

  本发明涉及生物活性的杂环吡咯类似物，如咪唑、噻唑、噁唑和吡唑，能够与CB1和/或CB2大麻素受体相互作用。其中一方面揭示了杂环吡咯类似物作为CB1和/或CB2受体的拮抗剂。另一方面揭示了具有对CB1或CB2大麻素受体选择性的杂环吡咯类似物。还揭示了使用所述类似物的制药制剂和将所述类似物在治疗上有效量下给予以提供生理效应的方法。
• Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors
  申请人：Makriyannis Alexandros

  公开号：US20120095047A1

  公开（公告）日：2012-04-19

  Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for the CB1 or CB2 cannabinoid receptor. Also disclosed are pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect.

  本发明涉及一种生物活性的杂环吡咯类似物，例如咪唑、噻唑、噁唑和吡唑，能够与CB1和/或CB2大麻素受体相互作用。其中一方面揭示了作为CB1和/或CB2受体拮抗剂的杂环吡咯类似物。另一方面揭示了具有CB1或CB2大麻素受体选择性的杂环吡咯类似物。还揭示了使用所述类似物的制药制剂以及给予治疗有效量的所述类似物以提供生理效应的方法。
• FIVE-MEMBERED HETEROCYCLIC DERIVATIVE
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1621537A1

  公开（公告）日：2006-02-01

  The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

  本发明涉及一种由式 (I) 代表的化合物： 本发明涉及一种由式（I）代表的化合物：该化合物的一种盐，或该化合物或该盐的一种溶解物；含有该化合物、该盐和该溶解物中任何一种的药物；含有该化合物、该盐和该溶解物中任何一种的预防和/或治疗缺血性疾病的药物；以及含有该化合物、该盐和该溶解物中任何一种的血小板凝集抑制剂。本发明的化合物可作为强血小板凝集抑制剂而不抑制 COX-1 或 COX-2。